<DOC>
	<DOCNO>NCT00680134</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 1 % 5 % AN2690 solution treatment distal , subungual onychomycosis great toenail .</brief_summary>
	<brief_title>Safety Efficacy Evaluation Topically Applied AN2690 Solutions Subjects With Onychomycosis</brief_title>
	<detailed_description>The first group 30 protocol-qualified subject assign Treatment Group 1 give 1 % AN2690 Solution . The second group 30 protocol-qualified subject assign Treatment Group 2 give 5 % AN2690 Solution .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tavaborole</mesh_term>
	<criteria>Witnessed , sign informed consent approve Institutional Review Board/Ethics Committee A sign Health Insurance Portability Accountability Act ( HIPAA ) authorization form permit use disclosure subject 's individually identifiable health information enrol United States America Male female subject race 18 65 year age Subjects diagnosis onychomycosis least one great toenail positive KOH wet mount positive fungal culture dermatophyte specie Onychomycosis involve 2060 % affect great toenail determine baseline ( Day1 ) visual inspection nail trim The combined thickness distal nail plate associate hyperkeratotic nail bed &lt; 3 mm Affected great toenail treat capable regrowth document history recent observation least 2 mm growth Females childbearing potential use highly effective method birth control ( e.g . implant , injectables , combine oral contraceptive , intrauterine contraceptive device ) study Subjects unwilling refrain use nail cosmetic clear color nail lacquer screen visit end study Subjects chronic moccasin type T. pedis Subjects history fail previous topical antifungal therapy onychomycosis Diabetes mellitus require treatment diet exercise Subjects undergone specify washout period ( ) follow topical preparation subject require concurrent use follow topical medication : 1 . Topical antifungal apply toenail ( include antifungal treatment T. pedis ) : 12 week 2 . Antiinflammatories , corticosteroid , topical immunomodulators ( treatment area ) : 2 week Subjects undergone specify washout period ( ) follow systemic medication subject require concurrent use follow systemic medication : 1 . Corticosteroids ( include intramuscular injection ) : 2 week 2 . Antifungals treatment onychomycosis systemic antifungal know activity dermatophyte specie : 24 week 3 . Systemic immunomodulators : 4 week Treatment type cancer within last 6 month History significant internal disease Subjects medical history current past psoriasis skin and/or nails Concurrent lichen planus Subjects know allergic test product ( ) components test product ( ) history hypersensitivity allergic reaction study preparation describe Investigator 's Brochure Nail anatomic abnormality toe , e.g. , genetic nail disorder , primentary disorder , onychogryphosis , trauma nail ( ) treat AIDS AIDS relate complex History street drug alcohol abuse Any subject able meet study attendance requirement Subjects participated trial investigational drug device within 60 day prior enrollment participation research study concurrent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Onychomycosis</keyword>
	<keyword>Fungal Nail</keyword>
</DOC>